Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare
The centerpiece of the deal is orelabrutinib, a BTK inhibitor in late-stage development for multiple sclerosis that Biogen once paid $125 million for but abandoned after less than two years of testing.
Zenas Bets $2B+ in Autoimmune Agreement With Chinese Firm InnoCare Read More »
